A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
ID Number 13-0423Principal Investigator(s)
Myron E. Schwartz
Department(s) or Division(s)
The purpose of this study is to assess if regorafenib in combination with Best Supportive Care is safe and will slow down the growth of tumor or even shrink the tumor and result in increased survival in subjects who experienced failure of previous systemic sorafenib treatment.
Best Supportive Care (BSC) is care given to a cancer patient to help lessen symptoms caused by the cancer. Examples of such care are (1) appetite stimulants to help improve your appetite, (2) nutritional supplements to aid in weight gain and maintaining body protein levels, (3) pain medication to treat any cancer related pain, (4) intravenous fluid (through a vein in the arm) for dehydration (excessive loss of water from the body) or (5) intravenous blood products for anemia (decreased red blood cells) which may lead to weakness, breathlessness and reduced energy.
Recruiting Patients: Yes